In Germany, four vaccines can now protect against Covid 19 infection.
Actually, because the Johnson & Johnson vaccine is rarely used.
Munich - In mid-March, the European Medicines Agency (EMA) released the Johnson & Johnson vaccine as the fourth vaccine in the fight against the coronavirus.
But it is rarely used in Germany.
If you look at the statistics, mostly only Biontech, Astrazeneca and Moderna appear.
There are several reasons for that.
Corona vaccine from Johnson & Johnson - 94 percent remain
Around 94 percent of the doses of the US vaccine that have already been delivered have not yet been used in Germany, as
According to data from the Federal Ministry of Health, around 232,800 doses had been delivered to the federal states by the end of April.
Another 192,000 are to follow in May.
Actually it should have been significantly more.
When the vaccine began shipping to the European Union in April, the manufacturer had committed to delivering 55 million doses by the end of June.
Ten million should have gone to Germany.
But then there were delivery bottlenecks at the American pharmaceutical company.
Therefore, the planned start of vaccination in the family doctor's practices with the vaccine has been postponed.
But even the quantities already delivered have hardly been inoculated so far.
only 15,444 cans are said to
have been used.
The active ingredient offers two decisive advantages: It can be stored comparatively easily and only one dose is necessary for complete immunization.
The Johnson & Johnson vaccine has so far only been used in small quantities.
© Federico Gambarini / dpa
Lack of strategy when vaccinating with Johnson & Johnson - that's the problem
After the delays, the federal states seem to be lacking a suitable strategy. Because it is actually particularly suitable for those people for whom a second vaccination cannot be guaranteed or in places where the storage conditions are not suitable for Biontech or Moderna. It could therefore be used, for example, for the homeless, in accommodation for refugees, auxiliary facilities such as women's shelters, in districts with a particularly high incidence or with company doctors in companies.
The first attempts to do this have probably already been made in various federal states.
However, by far not everywhere and even where actions took place, the available quantities according to
information were not
In addition, there were several technical errors in the reporting of these vaccinations, which is why the numbers could be skewed.
Chaos due to a possible Stiko recommendation?
Vaccine maybe only for over 60s
In addition, the Standing Vaccination Commission (Stiko) will probably only give the vaccine in Germany a recommendation for over 60-year-olds.
The reason for this is that - similar to Astrazeneca - in rare cases cerebral vein thrombosis occurred in connection with the vaccination.
The USA had therefore temporarily suspended the vaccinations.
The EMA approved the active ingredient again after a new test.
Younger people should be allowed to continue using the vaccine after being informed by a doctor.
(mam / dpa)
List of rubric lists: © Federico Gambarini / dpa